Striatal Metabolic Rate and Clinical Response to Neuroleptics in Schizophrenia

Archives of General Psychiatry

Volumn 49, Issue 12, 1992, Pages 966-974

  Buchsbaum, Monte S ^a,e   Potkin, Steven G ^a   Siegel, Benjamin V ^a   Lohr, James ^c   Katz, Mark ^a   Gottschalk, Louis A ^a   Gulasekaram, Bala ^d   Marshall, John F ^a   Lottenberg, Stephen ^a   Teng, Chuck Ying ^a   Abel, Lennart ^a   Plon, Lawrence ^b   Bunney, William E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Metropolitan State Hospital   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO;

ADULT; ARTICLE; BRAIN METABOLISM; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RESPONSE; FEMALE; FRONTAL CORTEX; HUMAN; MALE; METABOLIC RATE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA;

ADULT; BASAL GANGLIA; CAUDATE NUCLEUS; CEREBRAL CORTEX; DEOXYGLUCOSE; DOUBLE-BLIND METHOD; FEMALE; FLUDEOXYGLUCOSE F 18; GLUCOSE; HALOPERIDOL; HUMAN; MALE; MIDDLE AGE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PUTAMEN; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0026467217     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1992.01820120054008     Document Type: Article

References (50)

1. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung TJK, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science. 1986;234:1558-1563.
2. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986;231: 258-261.
3. Carpenter WT Jr, Heinrichs DW. Treatment-relevant subtypes of schizophrenia. J Nerv Ment Dis. 1981;169:113-119.
4. Bunney WE Jr. A view of the neurosciences and psychopharmacology of the major psychoses—present and future. Presented at the Collegium Internationale Neuro-Psychopharmacologicum Congress; 1988; Munich, Germany.
5. Bunney WE Jr. Dopamine-glutamate interactions in schizophrenia. In: Program and abstracts of the American College of Neuropsychopharmacology; December 10-14, 1990; San Juan, Puerto Rico. Abstract, page 60.
6. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull. 1990;16:425-432.
7. Brown WA, Herz LR. Response to neuroleptic drugs as a device for classifying schizophrenia. Schizophr Bull. 1989;15:123-129.
8. Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychol Med. 1988; 8:873-885.
9. Hyttel J, Larsen J-J, Christensen AV, Arnt J. Receptor binding profiles of neuroleptics. Psychopharmacol Ser. 1985;2:9-16.
10. Kozlowski MR, Marshall JF. Plasticity of [14]C]2-deoxy-D-glucose incorporation into neostriatum and related structures in response to dopamine neuron damage and apomorphine replacement. Brain Res. 1980;197:167-183.
11. Wooten GF, Collins RC. Metabolic effects of unilateral lesion of the substantia nigra. J Neurosci. 1981;1:285-291.
12. Carvey PM, Braun AR, Kao LC, Klawans HL. Effects of dopamine antagonists and apomorphine on regional energy metabolism in rat CNS. Clin Neuropharmacol. 1987;10:247-260.
13. Pizzolato G, Doncrant TT, Larson DM, Rapoport SI. Reduced metabolic response of rat brain to haloperidol greater after chronic treatment. Brain Res. 1985;337:1-9.
14. Buchsbaum MS, Wu JC, DeLisi LE, Holcomb HH, Hazlett E, CooperLangston K, Kessler R. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biol Psychiatry. 1987;22:479-494.
15. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
16. Szechtman H, Nahmias C, Garnett ES, Firnau G, Brown GM, Kaplan RD, Cleghorn JM. Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry. 1988;45:523-532.
17. Cohen RM, Semple WE, Gross M, Nordahl TE, Holcomb HH, Dowling S, Pickar D. The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci. 1988;43:1141-1150.
18. Wik G, Wiesel FA, Sjogren I, Blomqvist G, Greitz T, Stone-Elander S. Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography. Psychopharmacology (Berl). 1989;97:309-318.
19. Bartlett EJ, Wolkin A, Brodie JD, Laska EM, Wolf AP. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Res: Neuroimaging. 1991;40:115-124.
20. Resnick SM, Gur RE, Alavi A, Gur RC, Reivich M. Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatry Res. 1988;24:1-11.
21. Buchsbaum MS, Potkin SG, Marshall JF, Lottenberg S, Tang CY, Heh CW, Tafalla R, Reynolds C, Abel L, Plon L, Bunney WE Jr. Effects of colozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology. 1992;6:155-164.
22. Seeman P. Brain dopamine receptors. Pharmacol Rev. 1980;32:229-313.
23. Anderson PH, Gronvald FC, Jansen JA. A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH23390 binding in rat striatum. Life Sci. 1985;37:1971-1983.
24. Joyce JN, Sapp DW, Marshall JF. Human striatal dopamine receptors are organized in compartments. Proc Natl Acad Sci U S A. 1986;83:8002-8006.
25. Nuechterlein KH, Parasuraman R, Jiang Q. Visual sustained attention: image degradation produces rapid decrement over time. Science. 1983;220: 327-329.
26. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L. The Continuous Performance Test, Identical Pairs Version, II: contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res. 1989;29:65-85.
27. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous Performance Test, Identical Pairs Version (CPT-IP): new findings about sustained attention in normal families. Psychiatry Res. 1988; 26:223-238.
28. Buchsbaum MS, Mirsky AF, DeLisi LE, Morihisa J, Karson CN, Mendelson WB, King AC, Johnson J, Kessler R. The Genain quadruplets: electrophysiological, positron emission and x-ray tomographic studies. Psychiatry Res. 1984;13:95-108.
29. Buchsbaum MS, Gillin JC, Wu J, Hazlett E, Sicotte N, DuPont RM. Regional cerebral glucose metabolic rate in human sleep assessed by positron emission tomography. Life Sci. 1989;45:1349-1356.
30. Matsui T, Hirano A. An Atlas of the Human Brain for Computerized Tomography. New York, NY: lgaku-Shoin Medical Publishers Inc; 1978.
31. Dixon WJ. BMD Biomedical Computer Programs. Berkeley; Calif: University of California Press; 1982.
32. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357-381.
33. Buchsbaum MS, Nuechterlein KH, Haier RJ, Wu J, Sicotte N, Hazlett E, Asarnow R, Potkin S, Guich S. Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography. Br J Psychiatry. 1990;156:216-227.
34. Goldman-Rakic PS, Selemon LD. Topography of corticostriatal projections in nonhuman primates and implications for functional parcellation of the neostriatum. In: Jones EG, Peters A, eds. Cerebral Cortex. New York, NY: Plenum Press; 1986.
35. Joyce JN, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse. 1988;2:546-557.
36. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain: Three-dimensional Proportional System: An Approach to Cerebral Imaging. New York, NY: Thieme-Stratton Inc; 1988.
37. Honigfeld G, Patin J, Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Ther. 1984;1:77-97.
38. Marder SR, Asarnow RF, Van Putten T. Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Res. 1984;13:41-49.
39. Harvey PD, Putnam KM, Davidson M, Kahn RS, Powchik P, McQueeney R, Keefe RSE, Davis KL. Brief neuroleptic discontinuation and clinical symptoms in kraepelinian and non-kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991;38:285-292.
40. Volkow ND, Brodie JD, Wolf AP, Angrist B, Russell J, Cancro R. Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. J Neurol Neurosurg Psychiatry. 1986;49:1199-1202.
41. Cleghorn JM, Szechtman H, Garnett ES, Nahmias C, Brown GM, Kaplan RD, Szechtman B, Franco S. Apomorphine effects on brain metabolism in neuroleptic-naive schizophrenic patients. Psychiatry Res: Neuroimaging. 1991;40:135-153.
42. Wolkin A, Angrist B, Wolf A, Brodie J, Wolkin B, Jaeger J, Cancro R, Rotrosen J. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology (Berl). 1987;92:241-246.
43. Bartlett EJ, Barouche F, Brodie JD, Wolkin A, Angrist B, Rotrosen J, Wolf AP. Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia. Psychiatry Res: Neuroimaging. 1991;40:11-20.
44. Buchsbaum MS, Tafalla RJ, Reynolds C, Trenary M, Burgwald L, Potkin S, Bunney WE Jr. Drug effects on brain lateralization in the basal ganglia of schizophrenics. In: Willner P, Scheel-Kruger J, eds. The Mesolimbic Dopamine System: From Motivation to Action. New York, NY: John Wiley & Sons Inc; 1991:529-538.
45. Bracha HS. Asymmetric rotational (circling) behavior—a dopaminerelated asymmetry: preliminary findings in unmedicated and nevermedicated schizophrenic patients. Biol Psychiatry. 1987;22:995-1003.
46. McCulloch J, Savaki HE, Sokoloff L. Distribution of effects of haloperidol on energy metabolism in the rat brain. Brain Res. 1982;243:81-90.
47. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry. 1989;146:905-908.
48. Seeman P, Nizik HB, Guan H-C, Booth G, Ulpian C. Link between D, and D2 dopamine receptors is reduced in schizophrenia and Huntingtondiseased brain. Proc Natl Acad Sci U S A. 1989;86:10156-10160.
49. Friedhoff AJ. A strategy for developing novel drugs for treatment of schizophrenia. Schizophr Bull. 1983;9:555-562.
50. Buchsbaum MS, Haier RJ, Potkin SG, Nuechterlein K, Bracha HS, Lohr J, Wu J, Lottenberg S, Jerabek PA, Trenary M, Tafalla R, Reynolds C, Bunney WE Jr. Fronto-striatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry. 1992;49:974-982.